FDA Guidance: FDA Drug Safety Priorities 2023 Report

Highlights from the FDA Drug Safety Priorities 2023 Report

The FDA's Center for Drug Evaluation and Research (CDER) recently released its FDA Drug Safety Priorities 2023 Report, detailing a number of advancements and initiatives that safeguard the enhanced safety of both prescription and over-the-counter (OTC) medications, underscoring the agency's commitment to safety surveillance and risk evaluation whatever the status of the medicinal products.

Within the FDA Drug Safety Priorities 2023 Report, the FDA outlines several key areas of focus. These include post-marketing drug safety, CDER safety surveillance, and ongoing efforts around regulatory intelligence reporting across the pharmaceutical industry.

Core Focus Areas in the FDA Drug Safety Priorities 2023 Report

Key initiatives highlighted in the FDA Drug Safety Priorities 2023 Report focus on critical areas across the drug lifecycle:

• Overdose Mitigation & Approvals: Addressing the drug overdose crisis mitigation and measures to reduce such occurrences, most notably highlighting the milestone OTC naloxone FDA approval.

• Quality & Contaminants Control: Safeguarding generic medication quality (GMP) and efforts to manage impurities, including updating compliance alignment for nitrosamine impurities guidelines.

• Surveillance Technologies: Expanding the integration of Real-World Evidence (RWE) in pharmacovigilance and modernizing Risk Evaluation and Mitigation Strategies (REMS) to enhance patient outcome monitoring.

Due to the broad implications this has on the pharmaceutical industry—affecting drug manufacturers, healthcare providers, and patients—companies are encouraged to align with these priorities and make stakeholders aware of the FDA's multidisciplinary approach to enhancing drug safety.

Industry Implications and Regulatory Compliance Strategy

As best practice, in order to align these practices accordingly, companies are urged to review the full FDA pharmacovigilance guidance directly on the FDA's official website and understand the detailed requirements to ensure compliance with the latest safety standards.

To maintain robust compliance and seamless data processing, organizations can rely on specialized tools like RAPTAR to streamline reporting pipelines. Furthermore, exploring tailored Regulatory Strategy Services and broader PharSafer Services helps teams navigate shifting global regulatory expectations effectively.

For any questions or assistance on how to best navigate the FDA Drug Safety Priorities 2023 Report updates and their implications for your Pharmacovigilance Services, including the full FDA document, please do not hesitate to contact our team.